Valuation : Prothena Corporation plc

Market Cap 458M 395M 374M 339M 636M 43.8B 639M 4.44B 1.71B 22.28B 1.72B 1.68B 70.41B P/E 2026 *
81.2x
P/E 2027 * -9.6x
Enterprise Value 458M 395M 374M 339M 636M 43.8B 639M 4.44B 1.71B 22.28B 1.72B 1.68B 70.41B EV / Sales 2026 *
5.51x
EV / Sales 2027 * 18.8x
Free-Float
77.85%
Yield 2026 *
-
Yield 2027 * -
1 day-1.00%
1 week-9.06%
Current month-4.49%
1 month-3.15%
3 months+8.11%
6 months-6.78%
Current year-6.49%
1 week 8.76
Extreme 8.765
9.67
1 month 8.58
Extreme 8.58
9.87
Current year 7.73
Extreme 7.73
11.8
1 year 7.73
Extreme 7.73
11.8
3 years 4.32
Extreme 4.32
56.04
5 years 4.32
Extreme 4.32
79.75
10 years 4.32
Extreme 4.32
79.75
Manager TitleAgeSince
Chief Executive Officer 57 2016-09-29
Director of Finance/CFO 52 2013-03-31
Chief Operating Officer 52 2021-09-28
Director TitleAgeSince
Chairman 76 2012-12-19
Director/Board Member 72 2012-12-19
Director/Board Member 63 2012-12-19
Date Insider Type Main position Quantity % Market Cap. Importance
9/2/26 Buy 27,000 0.0526%
8/20/26 Buy 50,000 0.0955%
8/18/26 Don -627,553 1.1987%
Change 5-day change 1-year change 3-year change Capi.($)
-1.00%-9.06%+5.93%-83.60% 458M
-2.11%-1.68%+44.52%+95.15% 66.93B
-0.23%-4.45%+30.39%+73.64% 61.97B
+1.67%+2.47%-11.23%+388.34% 28.27B
-1.05%-4.43%+30.56%+10.07% 24.59B
+0.34%-6.78%-7.27%-17.99% 24.3B
+0.43%-3.37%+14.85%-19.29% 19.41B
-3.03%-2.29%+185.12%+334.07% 16.77B
-1.94%-4.94%-5.29%+495.65% 14.18B
-2.28%-4.90%+43.64%+155.21% 13.91B
Average -0.92%-4.02%+33.12%+143.12% 27.08B
Weighted average by Cap. -0.84%-3.07%+33.41%+133.30%

Financials

2026 *2027 *
Net sales 83.16M 71.65M 67.84M 61.49M 115M 7.94B 116M 806M 310M 4.04B 312M 305M 12.77B 24.38M 21M 19.89M 18.02M 33.81M 2.33B 33.99M 236M 90.82M 1.18B 91.54M 89.53M 3.74B
Net income 6.22M 5.36M 5.08M 4.6M 8.63M 595M 8.68M 60.31M 23.19M 303M 23.38M 22.86M 956M -49.57M -42.71M -40.44M -36.66M -68.77M -4.74B -69.12M -480M -185M -2.41B -186M -182M -7.61B
Net Debt - -
Logo Prothena Corporation plc
Prothena Corporation plc is an Ireland-based late-stage clinical biotechnology company. The Company is engaged in protein dysregulation and a pipeline of investigational therapeutics for rare peripheral amyloid diseases. The Company is advancing a pipeline of therapeutic candidates for a range of indications and targets to integrate scientific insights around neurological dysfunction and the biology of misfolded proteins. The Company’s pipeline includes both wholly owned and partnered programs being developed for the potential treatment of diseases, including AL amyloidosis, ATTR amyloidosis, Alzheimer’s disease, Parkinson’s disease and a range of other neurodegenerative diseases. Its clinical programs include birtamimab for the potential treatment of AL amyloidosis, prasinezumab for the potential treatment of Parkinson’s disease, NNC6019/PRX004 for the potential treatment of ATTR amyloidosis, and PRX005 and PRX012 for the potential treatment of Alzheimer’s disease.
Employees
67
Date Price Change Volume
26-09-11 US$8.930 -1.00% 376,275
26-09-10 US$9.020 -3.01% 310,912
26-09-09 US$9.300 -2.52% 294,558
26-09-08 US$9.540 -2.85% 305,440
26-09-04 US$9.820 +2.29% 383,928
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
BBB
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
6
Last Close Price
8.930USD
Average target price
21.40USD
Spread / Average Target
+139.64%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. PRTA Stock
40% Discount: Identify Tomorrow's Best Investments With The Best Subscriber-Only Tools!
d
:
:
SEIZE THE OFFER!